Biosafety in the preparation and processing of cytology specimens with potential coronavirus (COVID-19) infection: Perspectives from Taiwan

Cancer Cytopathol. 2020 May;128(5):309-316. doi: 10.1002/cncy.22280. Epub 2020 Apr 7.

Abstract

This commentary focuses on the cytopathology laboratory, the authors' experiences with coronavirus (COVID‐19) in Taiwan, and current guidelines on COVID‐19 infection prevention and control. The objective of this report is to provide cytopathology professionals a timely, in‐depth, evidence‐based review of biosafety practices for those at risk for coronavirus (COVID‐19) infection.

Keywords: COVID-19; biosafety; coronavirus; cytology; pneumonia.

Publication types

  • Review

MeSH terms

  • Betacoronavirus / isolation & purification
  • COVID-19
  • Containment of Biohazards / methods*
  • Containment of Biohazards / standards
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / pathology*
  • Coronavirus Infections / transmission
  • Coronavirus Infections / virology
  • Cytological Techniques / methods*
  • Cytological Techniques / standards
  • Humans
  • Infection Control / methods
  • Infection Control / standards
  • Infectious Disease Transmission, Patient-to-Professional / prevention & control*
  • Pandemics
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / pathology*
  • Pneumonia, Viral / transmission
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Specimen Handling / methods
  • Specimen Handling / standards
  • Taiwan / epidemiology